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Abstract
Few studies covering all patient groups and specialties are available regarding the outcome of nosocomial bloodstream infections
(BSI). We analyzed the role of patient characteristics and causative pathogens of nosocomial BSIs reported by the hospitals
participating in national surveillance in Finland during 1999–2014, in terms of outcome, with particular interest in those leading
to death within 2 days (i.e. early death). National nosocomial BSI surveillance was laboratory-based and hospital-wide. Data on
nosocomial BSIs was collected by infection control nurses, and dates of death were obtained from the national population registry
with linkage to national identity codes. A total of 17,767 nosocomial BSIs were identified; 557 BSIs (3%) were fatal within
2 days and 1150 (6%) within 1 week. The 1-month case fatality was 14% (2460 BSIs), and 23% of the deaths occurred within
2 days and 47% within 1 week. The patients who died early were older than those who survived > 28 days, and their BSIs were
more often related to intensive care. Gram-positive bacteria caused over half of the BSIs of patients who survived, whereas gram-
negative bacteria, especially Pseudomonas aeruginosa, caused more often BSIs of patients who died early, and fungi BSIs of
patients who died within 1 week. A significant portion of patients with nosocomial BSIs died early, which underlines the
importance of rapid recognition of BSI. Hospital-wide surveillance data of causative pathogens can be utilized when composing
recommendations for empiric antimicrobial treatment in collaboration with clinicians, as well as when promoting infection
prevention.
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Introduction
Nosocomial bloodstream infections (BSI) constitute a major
part of all BSIs and are related to significant mortality and
morbidity. The case fatality of nosocomial BSIs has varied,
with reported all-cause 30-day mortality between 24 and 28%
[1–3] and in-hospital case fatality around 30% [4–7].
So far, rather limited surveillance data has been available
on the outcome and the timing of death of nosocomial BSIs, as
previous studies have mostly focused on a specific causative
agent of BSI [8–10], or the data has been obtained from a
single tertiary care hospital [11] or few intensive care units
(ICU) [12, 13], thus representing a selected patient population.
A significant proportion of BSI-associated deaths have been
previously shown to occur early, within 2 days after the first
positive blood culture [14–16]. The knowledge of the predis-
posing factors related to these early deaths is scarce, although
it is likely that the appropriateness of the empiric antimicrobial
treatment plays an important role in early mortality, as the
initial blood culture results typically become available not
until the second to third day after taking the specimen.
In this study, we analyzed patients’ characteristics and
causative pathogens of all nosocomial BSIs in the hospitals
participating in the Finnish Hospital Infection Program in
Finland during 1999–2014 in terms of outcome and timing
of death. To our knowledge, similar data on the timing of
death has not been presented previously. The objective of
our study was to evaluate the role of different factors for mor-
tality of patients with nosocomial BSI and particularly among
patients dying early.
* Keiju S. K. Kontula
keiju.kontula@hus.fi
1 Division of Infectious Diseases, Inflammation Center, University of
Helsinki and Helsinki University Hospital, P.O. Box 340,
00029 Helsinki, Finland
2 Department of Health Security, National Institute for Health and
Welfare, P.O. Box 30, 00271 Helsinki, Finland
European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:945–952
https://doi.org/10.1007/s10096-018-3211-0
Materials and methods
Hospitals
In Finland (population 5.5 million in 2014), the national
healthcare system is publicly funded and is organized into
20 geographically and administratively defined healthcare dis-
tricts (HD), with populations ranging from about 44,000 to 1.6
million. Fifteen HDs have secondary care hospitals and five
also provide tertiary care services. Four acute care hospitals
from three HDs started in a surveillance project called Finnish
Hospital Infection Program (SIRO) in 1999. Participating hos-
pitals increased from the original 4 by 0–2 hospitals per year
to 18 in 2014: 4/5 tertiary care hospitals, 9/15 secondary care
hospitals, and 5/~ 30 other acute care hospitals representing
altogether 13 HDs. Surveillance was active, prospective, and
hospital-wide, covering all patients admitted to departments
offering acute care [17].
Case finding and definitions
The instructions generally advise that blood samples should
be obtained for culture if the temperature of a patient is >
38 °C and/or in case of other symptoms or signs compatible
with BSI (e.g. hypothermia, hypotonia). Local infection con-
trol nurses in each hospital reviewed regularly the laboratory
database for positive blood culture results. The Centers of
Disease Control and Prevention definition for nosocomial
BSI was used, and only laboratory-confirmed BSIs were in-
cluded in the study [18]. All BSIs in neonates were regarded
as nosocomial infections.
Primary BSI refers to bacteremia or fungemia for which
there was no documented focal source, including those
resulting from intravenous or arterial catheter infections.
Secondary BSI was defined as an infection that developed as
a consequence of a documented infection with the same mi-
croorganism at another body site. Polymicrobial BSI refers to
infections due to more than one microorganism in blood cul-
tures within a 48-h period. Of the underlying conditions and
possible risk factors, delivery, newborn status, hematological/
solid malignancy, organ transplantation, and hemodialysis
were recorded, as well as the presence of a central venous line.
All patients who entered the operating room were recorded as
having had surgery. Only patients who were hospitalized for at
least 24 h in ICU before the occurrence of BSI were consid-
ered to have been exposed to intensive care. All BSIs that
became evident during the intensive care stay or within 48 h
after discharge from ICU were considered to be related to
intensive care.
Clinical information and microbiological data were record-
ed by the local infection control nurses on a standardized case-
record form sent monthly to the National Institute for Health
and Welfare and entered into a common database.
Outcome
The case fatality at 2, 7, and 28 days after the first positive
blood culture of a particular patient was obtained from the
national population registry by use of national identity codes.
All deaths occurring within the first 2 days after the onset of
the infection (i.e. after taking the first positive blood culture,
day 0) were referred to as early deaths.
Microbiological resistance
Both antibiotic-resistant and intermediately susceptible organ-
isms were considered to be resistant when resistance percent-
ages were calculated for the microorganisms. Extended-
spectrum β-lactamase-producing (ESBL) Escherichia coli
and Klebsiella pneumoniae were defined as resistant or inter-
mediately susceptible to third-generation cephalosporins.
Multidrug-resistant (MDR) Pseudomonas aeruginosa and
Acinetobacter were resistant or intermediately susceptible to
c a r b a p e n em s , a n d c a r b a p e n ema s e - p r o d u c i n g
Enterobacteriaceae (CPE) refers to E. coli, K. pneumoniae,
and Enterobacter sp. resistant or intermediately susceptible
to carbapenems.
Analyses and statistics
Data was analyzed using IBM SPSS Statistics version 22 and
Stata 14. Univariate analysis of categorical variables was done
with the χ2 test, using Yates’s correction, or Fisher’s exact test,
as appropriate. The differences in distributions between con-
tinuous variables were tested by the Kruskal-Wallis test.
Piecewise exponential regression model was used to evaluate
the effects of patient characteristics and causative pathogens
on the hazard of death within different time points of death (0–
2, 3–7, 8–28, and > 28 days after the positive blood culture)
(Stata 14, Texas, USA).
Results
In the 18 hospitals participating in SIRO, a total of 17,893
nosocomial BSIs were identified during 1999–2014; 126
BSIs (0.7%) were excluded because the patients’ reported
national identity codes were inadequate, leaving 17,767 nos-
ocomial BSIs among 15,784 patients in the study. The median
age of the patients was 60 years (range 0–103); 15% were
children < 16 years, and 59% of the patients were males. Of
the BSIs, 22% were related to intensive care, and 26% were
among patients with a hematological malignancy and 20%
among those with a solid malignancy. There were 1471
(8%) BSIs in newborns and 348 (2%) BSIs in patients with
admission for obstetric care. Of all BSIs, 27%were secondary,
946 Eur J Clin Microbiol Infect Dis (2018) 37:945–952
and the urinary tract (35%) and surgical wound (20%) were
the most common sources of infection.
Of all BSIs, 57% were caused by gram-positive bacteria,
27% by gram-negative bacteria, 4% by fungi, 2% by anaer-
obes, and 9% were polymicrobial and 1% was not classified.
Coagulase-negative staphylococcus (CNS) was the most com-
mon single pathogen (22% of all BSIs), followed by
Staphylococcus aureus (15%), E. coli (12%), enterococci
(8%), and P. aeruginosa (4%). Altogether, 398 (2.2%) BSIs
were caused by MDR microbes. The percentage of BSIs
caused by MDR microbes increased from 0.4% in 1999 to
3.4% in 2014; mostly, the increase occurred in ESBL E. coli
and K. pneumoniae (from 0 to 11.3%, of all E. coli and
K. pneumoniae BSIs).
Of the BSIs, 557 (3% of all BSIs) were fatal within 2 days
(i.e. early deaths) and 1150 (6% of all BSIs) within 1 week
(Table 1). The 1-month case fatality was 14% (2460 BSIs),
and 23% of these deaths occurred within 2 days and 47%
within 1 week. The differences in the characteristics of the
BSIs according to the timing of death (within 2 days, within
3–7 days, within 8–28 days and alive at day 29) are summa-
rized in Table 1. The patients who died within 28 days were
significantly older than those who survived > 28 days, and the
patients with BSIs leading to early death were the oldest. BSIs
related to intensive care were significantly more often noted in
patients who died within 28 days than in patients who sur-
vived > 28 days, with the highest occurrence in patients who
died early. Among patients who died within 28 days, signifi-
cantly more solid malignancies were noted than among
patients who survived > 28 days, but no difference was ob-
served in the occurrence of hematological malignancies.
Central venous catheters, catheter-associated BSIs, and chron-
ic hemodialysis were most commonly seen in patients who
died within 3–7 days. There were more secondary bacteremias
in BSIs of patients who died within 2 days than in BSIs of
patients who survived > 28 days. Among patients with sec-
ondary bacteremias who died within 2 days, the respiratory
tract (24%) was the most common source of infection, follow-
ed by the gastrointestinal tract (21%) and the urinary tract
(21%). BSIs related to preceding hospital stay and outpatient
invasive procedure and BSIs related to admission for obstetric
care were most commonly observed in patients who survived
> 28 days, as well as BSIs in newborns.
Gram-positive bacteria caused 58% and gram-negative
27% of the BSIs of patients who survived > 28 days, whereas
among patients who died early, gram-negative bacteria caused
39% of the BSIs and gram-positive 36% (Table 2). The higher
occurrence of BSIs caused by gram-positive bacteria among
patients who survived > 28 days was mainly due to the higher
proportions of CNS (23%) and S. aureus (16%). Of the gram-
negative bacteria causing BSIs leading to early death, E. coli
(14%) and P. aeruginosa (12%) were the most common path-
ogens. Anaerobic bacteria were isolated in 4% of the BSIs
leading to early death, whereas in 2% of the BSIs in patients
who survived > 28 days. BSIs caused by fungi and
polymicrobial BSIs were significantly more often identified
among patients with BSIs who died within 28 days than in
patients who survived > 28 days. Candida albicans was the
Table 1 Patient characteristics of
nosocomial bloodstream
infections by timing of death in 18
Finnish hospitals during 1999–
2014
Characteristic Death within
2 days
n = 557
Death
within
3–7 days
n = 593
Death
within
8–28 days
n = 1310
Alive at day
29
n = 15,307
p value
Age in years, median (range) 69 (0–95) 68 (0–94) 67 (0–97) 59 (0–103) < 0.001
Male gender 340 (61%) 370 (62%) 759 (58%) 8953 (58%) 0.159
Intensive care 209 (38%) 199 (34%) 338 (26%) 3177 (21%) < 0.001
Central venous catheter 203 (36%) 283 (48%) 498 (38%) 5888 (38%) < 0.001
Catheter-associated BSI 152 (27%) 219 (37%) 374 (29%) 4989 (33%) < 0.001
Secondary bacteremia 161 (29%) 156 (26%) 383 (29%) 4160 (27%) 0.311
Preceding surgery 189 (34%) 181 (31%) 403 (31%) 4913 (32%) 0.471
Preceding hospital stay 88 (16%) 75 (13%) 213 (16%) 3170 (21%) < 0.001
Preceding outpatient invasive
procedure
32 (6%) 33 (6%) 93 (7%) 1436 (9%) < 0.001
Malignancy
Hematological 140 (25%) 158 (27%) 326 (25%) 4063 (27%) 0.535
Solid 148 (27%) 159 (27%) 410 (31%) 2804 (18%) < 0.001
Chronic hemodialysis 51 (9%) 69 (12%) 136 (10%) 1255 (8%) 0.001
Organ transplantation 13 (2%) 15 (3%) 36 (3%) 410 (3%) 0.956
Newborn status 25 (4%) 20 (3%) 26 (2%) 1400 (9%) < 0.001
Admission for obstetric care 1 (0.2%) 1 (0.2%) 3 (0.3%) 343 (2%) < 0.001
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most common causative fungus species in all BSI groups. The
proportions of BSIs caused by MDR microbes in total and by
MDR P. aeruginosa were highest in BSIs leading to early
death (Table 3). Instead, the proportions of BSIs caused by
methicillin-resistant S. aureus (MRSA) and ESBL E. coli or
K. pneumoniae were similar in all outcome groups.
Patient characteristics, causative pathogens, and all MDRmi-
crobes together listed in Tables 1, 2, and 3 were included in the
model, and the effect of age to the hazard for deathwas presented
by a 10 years increase in age. The hazard ratio associated with
intensive care admissionwas highest 3.6 in BSIs leading to death
within 0–2 days and decreased systematically thereafter to 0.85
in BSIs leading to death after 28 days (Fig. 1). Among the BSIs
leading to death after 28 days, the highest hazards for death were
noted in BSIs of patients with solid and hematological malig-
nancy and chronic hemodialysis. The highest hazard for death
concerning the causative pathogens of BSIs leading to death
within 0–2 days was among BSIs caused by P. aeruginosa,
whereas in the BSIs leading to death within 3–7 and 8–28 days,
the highest were noted among BSIs caused by fungi, enterococ-
ci, and polymicrobial BSIs. On the other hand, the hazards for
death associated with BSIs caused by MDR pathogens were
similar in all outcome groups of BSIs. In the model, the hazard
ratios are multiplicative, e.g., for a patient with a BSI related to
intensive care and caused by P. aeruginosa, the risk of dying
within 2 days was ten times higher compared to a patient with
BSI not related to intensive care and not caused byP. aeruginosa
(3.6 × 2.7 = 9.72), if their ages were within 10-year interval.
Discussion
In our study based on hospital-wide surveillance data of nearly
18,000 nosocomial BSIs, the 1-month case fatality was 14%,
and 23% of the deaths occurred within 2 days (2-day fatality,
3%) and 47%within 1 week (1-week fatality, 7%), after taking
the first blood culture specimen. We were able to accurately
determine the all-cause mortality within the three time points
Table 2 Causative pathogens of
nosocomial bloodstream
infections by timing of death in 18
Finnish hospitals during 1999–
2014
Pathogen Death within
2 days
n = 557
Death
within
3–7 days
n = 593
Death
within
8–28 days
n = 1310
Alive on day
29
n = 15,307
p value
Gram-positive bacteria 203 (36%) 293 (49%) 649 (50%) 8894 (58%) < 0.001
Staphylococcus aureus* 55 (10%) 63 (11%) 192 (15%) 2382 (16%)
Enterococci* 52 (9%)a 81 (14%) 155 (12%) 1123 (7%)
Coagulase-negative
staphylococci*
51 (9%)b 109 (18%) 231 (18%) 3507 (23%)
Streptococcus pneumoniae 10 (2%) 7 (1%) 3 (0.2%) 145 (1%)
Streptococcus agalactiae 8 (1%) 3 (0.5%) 4 (0.3%) 416 (3%)
Other 27 (5%)c 30 (5%) 64 (5%) 1321 (9%)
Gram-negative bacteria 216 (39%) 135 (23%) 334 (25%) 4115 (27%) < 0.001
Escherichia coli* 80 (14%) 44 (7%) 115 (9%) 1980 (13%)
Pseudomonas aeruginosa* 68 (12%) 29 (5%) 75 (6%) 485 (3%)
Klebsiella sp. 26 (5%) 24 (4%) 54 (4%) 702 (5%)
Enterobacter sp. 20 (4%) 14 (2%) 38 (3%) 403 (3%)
Serratia sp. 9 (2%) 11 (2%) 19 (1%) 158 (1%)
Other 13 (2%)d 13 (2%) 33 (3%) 387 (3%)
Anaerobes* 21 (4%) 14 (2%) 36 (3%) 372 (2%) 0.223
Fungi* 44 (8%) 66 (11%) 109 (8%) 516 (3%) < 0.001
Candida albicans 32 (6%) 50 (8%) 85 (6%) 332 (2%)
Non-albicans Candida 8 (1%) 15 (3%) 22 (2%) 155 (1%)
Other 4 (0.7%)e 1 (0.2%) 2 (0.2%) 29 (0.2%)
Polymicrobial* 73 (13%) 78 (13%) 166 (13%) 1301 (8%) < 0.001
a 33/52 Enterococcus faecium, 18/52 Enterococcus faecalis
b 26/51 Staphylococcus epidermidis
c 8/27 viridans streptococci, 5/27 Corynebacterium sp., 3/27 Streptococcus pyogenes
d 3/13 Stenotrophomonas maltofilia, 3/13 other or unidentified Pseudomonas sp.
e 3/4 unidentified Candida sp.
*Included in the piecewise exponential regression model
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by using data from the national population registry. Gram-
negative bacteria, especially P. aeruginosa, more often caused
BSIs of patients who died early than BSIs of patients who
survived > 28 days. On the other hand, BSIs caused by fungi
were most common among patients who died within 1 week,
and highest hazards for death after 28 days were noted in BSIs
Table 3 Causative multidrug-resistant pathogens of nosocomial bloodstream infections by timing of death in 18 Finnish hospitals during 1999–2014
Multidrug-resistant microbe Death within
2 days
n = 557
Death
within
3–7 days
n = 593
Death
within
8–28 days
n = 1310
Alive at day
29
n = 15,307
Methicillin-resistant Staphylococcus aureus (MRSA) (% of all BSIs) 3 (0.5%) 1 (0.2%) 12 (0.9%) 78 (0.5%)
Extended-spectrum β-lactamase-producing (ESBL) Escherichia coli or Klebsiella
pneumoniae (% of all BSIs)
10 (1.8%) 11 (1.9%) 18 (1.4%) 212 (1.4%)
Multidrug-resistant (MDR) Pseudomonas aeruginosa (% of all BSIs) 8 (1.4%) 3 (0.5%) 8 (0.6%) 20 (0.1%)
Vancomycin-resistant Enterococcus (VRE) (% of all BSIs) 0 1 (0.2%) 0 6 (0.04%)
Multidrug-resistant (MDR) Acinetobacter (% of all BSIs) 0 2 (0.3%) 0 5 (0.03%)
Carbapenemase-producing Enterobacteriaceae (CPE) (% of all BSIs) 0 0 0 0
Total of multi-resistant microbes* (% of all BSIs) 21 (3.8%) 18 (3.0%) 38 (2.9%) 321 (2.1%)
*Included in the piecewise exponential regression model
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Fig. 1 Hazard ratios for death of nosocomial bloodstream infections according to patient characteristics and causative pathogens in 18 Finnish hospitals
during 1999–2014: death during 0–2 days (a), during 3–7 days (b), during 8–28 days (c), and during > 28 days (d)
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of patients with malignancies. Patients with nosocomial BSIs
who died early were older, and these BSIs were more often
related to intensive care.
In the present study, the 1-month case fatality (14%) was
lower than in recent studies of nosocomial BSIs from North
America and Europe (24–28%) [1–3]. The case fatality of
nosocomial BSIs varies quite markedly between studies de-
pending on how it is reported (1-month, in-hospital mortality),
and it is also affected by the differences in the study popula-
tion, for example whether newborns and ICUs are included in
the study, and in the resistance profiles of microbes in the
setting. In-hospital mortality can be influenced by the length
of stay and differences in the healthcare delivery system.
In previous studies of all BSIs, a notable portion of BSI-
associated deaths have been shown to occur early, within
2 days after the first positive blood culture. In a prospective
survey from Denmark, nearly 5% of patients with BSI died
before the notification of positive blood cultures [14]. Also, in
a population-based study of BSIs in Finland during 2004–
2007, the 30-day case fatality was 13%, and one third of the
deaths happened within 2 days after the first blood culture was
taken [16]. So far, only limited data has been available on the
timing of death of specifically nosocomial BSIs. In the present
study, 23% of the deaths occurred early (3% of all BSIs)
which is slightly less than in studies including all BSIs. One
reason for this may be that treatment delays are more common
among patients with community-acquired BSIs, as shown in
our previous study of BSIs leading to early death [19].
The distributions of gram-positive and gram-negative bac-
teria and the most commonly seen single pathogens of our
total study population were similar to those of recent studies
of nosocomial BSIs [20–22]. In our study, some significant
differences were observed in the portions of causative patho-
gens of the BSIs depending on the timing of death of the
patients. Gram-negative bacteria, especially P. aeruginosa,
more often caused BSIs of patients who died early than BSIs
of patients in other outcome groups. BSIs caused by fungi
were more common among patients who died within 28 days
than among those who survived > 28 days, especially among
patients who died within 3–7 days, and the finding was also
confirmed by our regression model. In our former study of all
BSIs from Finland, the causative pathogens of healthcare-
associated BSIs leading to early death were similar: Gram-
negative bacteria were most often the causative pathogens
(53%) and P. aeruginosa was the single most common caus-
ative agent [19]. Moreover, half of the patients with HA-BSIs
who died early received inappropriate empiric antimicrobial
treatment, and 41% of the inappropriately treated patients had
a BSI caused by P. aeruginosa. Other previous reports have
also shown that a notable proportion of patients with nosoco-
mial BSIs receive ineffective initial antimicrobial therapy [1,
5, 6] and that inappropriate initial antimicrobial treatment of
BSI caused by P. aeruginosa is associated with greater
mortality compared to appropriate treatment [23]. Early and
effective antimicrobial therapy has been shown to reduce mor-
tality rates in patients with BSIs [24], which underlines the
importance of early recognition of the BSI and its healthcare
origin and adjustment of the empiric antimicrobial treatment
accordingly. Mortality to BSIs caused by fungi may reflect,
besides the severity of underlying conditions, the lack of an-
tifungal therapy or prophylaxis, as shown in a previous
Finnish study of candidemias during 2004–2007 [25].
Interestingly, in our piecewise exponential regression mod-
el, the hazard ratios for death associated with BSIs caused by
MDR pathogens were on the same level (1.4–1.6) in all out-
come groups. However, despite the increasing trend, only a
small proportion of all nosocomial BSIs in our study were
caused by MDR microbes (2.2%) with the highest proportion
(3.8%) in BSIs leading to early death.
Some differences were also observed in the sources of
secondary bacteremias of patients with nosocomial BSI de-
pending on the timing of death. The respiratory tract was the
most common source of infection among patients with BSIs
leading to early death, followed by the gastrointestinal tract
and the urinary tract, whereas among all patients regardless
of the outcome, the urinary tract and surgical wound were
the most common sources of infection of secondary bacter-
emias. Similar results were obtained in our previous study
of all BSIs leading to early death: The respiratory tract was
the most common site of infection, followed by the abdo-
men and the urinary tract [19]. On the other hand, in studies
including only nosocomial BSIs, regardless of the outcome,
intravascular device and the urinary tract have been the most
common sources of infection [1, 26].
We noted some significant differences in the underlying
conditions of the patients with nosocomial BSIs depending
on the outcome. Patients with BSIs who died early were
older, and these BSIs were more often related to ICU stay.
Catheter-associated BSIs and chronic hemodialysis were
most often perceived among patients with BSIs leading to
death within 3–7 days, whereas solid malignancies in pa-
tients with BSIs leading to death within 8–28 days. In our
previous population-based study from the Helsinki metro-
politan area of all BSIs leading to early death, we observed
that the patients who died early were significantly older
than the survivors, and that one third of these patients
had a rapidly fatal underlying disease or a prior do not
resuscitate order (DNR) indicating a poor overall condi-
tion, as expected [19].
We acknowledge that there are some limitations in this
study. First, since the study was based on surveillance data,
we did not have information on the patients’ specific underly-
ing diseases and the severity of their medical conditions, or
information on a possible DNR order of the patients, which
certainly have influenced the outcome of the patients. Second,
we did not have data onwhether the antimicrobial therapy was
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appropriate or not, nor data on delays in the commencement of
the treatment. However, as the proportions of BSIs caused by
MDR microbes have been low during the study period, these
microbes cannot be interpreted as a reason for severe outcome
of the patients in terms of inappropriate empiric antimicrobial
therapy. Rather, it is probable that the reason for initial inef-
fective antimicrobial treatment is at least partly due to the
intrinsic resistance of the causative pathogens, such as
P. aeruginosa and Enterobacter sp. or due to the lack of anti-
fungal treatment. Also, it should be noted that we did not
perform subgroup analyses for different Candida sp.
concerning the outcome and timing of death. Third, we did
not have information on the main cause of death of the pa-
tients, but it is likely that among the patients who died early,
the BSI was at least a contributing factor.
Our study covered nearly 18,000 nosocomial BSIs dur-
ing 16 consecutive years in all types of acute care hospitals
in different geographical areas of Finland. A notable por-
tion of deaths caused by nosocomial BSIs occurred early,
within 2 days. The patients who died early were older than
the survivors, and these BSIs were more often caused by
gram-negative bacteria, especially P. aeruginosa, and were
associated with ICU stay. It is likely that at least some of
these early deaths would not have been preventable due to
severe underlying condition of the patient. Early identifi-
cation of BSI and its healthcare origin, as well as prompt
initiation of appropriate antimicrobial treatment, are essen-
tial in prevention of fatal outcome of BSIs. The BSIs in our
study represented the causative pathogens of a particular
hospital participating in the surveillance project, thus pro-
viding with valuable data when promoting infection pre-
vention and when in collaboration with clinicians compos-
ing recommendations for empiric antimicrobial treatment
among different patient groups. In order to reduce the risk
of nosocomial BSIs during hospital stay, implementation
of infection control guidelines is highlighted.
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